CCX 872

Drug Profile

CCX 872

Alternative Names: CCX 872 B; CCX-872

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator ChemoCentryx
  • Class Small molecules
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Preclinical Non-alcoholic steatohepatitis
  • No development reported Metabolic disorders

Most Recent Events

  • 20 Jan 2017 Efficacy data from a phase Ib trial in Pancreatic cancer released by ChemoCentryx
  • 11 Nov 2016 Updated pharmacodynamics data from a preclinical study in Non-alcoholic steatohepatitis presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
  • 07 Nov 2016 ChemoCentryx plans a phase II trial for Pancreatic cancer (In combination) with a checkpoint inhibitor in 201780
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top